



SAFETY DATA SHEET

1. Identification

Product identifier	Emgality™		
Other means of identification			
Item Code	701324, PS3115, PS2377, PS1436, PS1424, 703179, 703178, 703177, 703176, 703175, 703174, 703173, PS2234, CT9739, CT9740, CT9741		
LY Number	LY2951742		
Recommended use	Pharmaceutical		
Recommended restrictions	None known.		
Manufacturer/Importer/Supplier/Distributor information			
Manufacturer			
Company name	Eli Lilly and Company		
Address	Lilly Corporate Center Indianapolis, IN 46285 United States		
Telephone	Phone:	+1-317-276-2000	
E-mail	lilly_msds@lilly.com		
Emergency phone number	CHEMTREC:	+1-800-424-9300	

2. Hazard(s) identification

Physical hazards	Not classified.
Health hazards	Not classified.
OSHA defined hazards	Not classified.
Label elements	
Hazard symbol	None.
Signal word	None.
Hazard statement	The mixture does not meet the criteria for classification.
Precautionary statement	
Prevention	Not available.
Response	Not available.
Storage	Not available.
Disposal	Not available.
Hazard(s) not otherwise classified (HNOC)	None known.
Supplemental information	None.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Galcanezumab		N/A	4 - 12

Composition comments Remaining components of this product are non-hazardous and/or are present at concentrations below reportable levels.

4. First-aid measures

Inhalation	Call a physician if symptoms develop or persist.
Skin contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	Get medical attention if symptoms occur.

Most important symptoms/effects, acute and delayed This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, this substance/preparation is considered unlikely to produce health effects through relevant routes of occupational exposures.

5. Fire-fighting measures

Suitable extinguishing media Use fire-extinguishing media appropriate for surrounding materials.

Unsuitable extinguishing media Not available.

Specific hazards arising from the chemical Not applicable.

Special protective equipment and precautions for firefighters Wear suitable protective equipment.

General fire hazards This product is an aqueous mixture which will not burn.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures Avoid inhalation of mists or aerosols.

Methods and materials for containment and cleaning up Use absorbent/adsorbent material to solidify liquids. Clean up promptly by sweeping or vacuum. Wear appropriate protective equipment and clothing during clean-up.

Environmental precautions Avoid release to the environment.

7. Handling and storage

Precautions for safe handling No specific recommendations.

Conditions for safe storage, including any incompatibilities Keep refrigerated Storage temperature: between 2 and 8 C.

8. Exposure controls/personal protection

Occupational exposure limits

Lilly (LEG)

Components

Type

Value

Galcanezumab

TWA (12hrs)

110 ug/m³

TWA (8hrs)

165 ug/m³

Biological limit values No biological exposure limits noted for the ingredient(s).

Appropriate engineering controls Contained handling practices preferred. If open handling is necessary, use control measures (i.e. ventilated enclosure, local exhaust ventilation) to maintain airborne levels below the occupational exposure level (OEL).

Individual protection measures, such as personal protective equipment

Eye/face protection Safety glasses with side shields recommended. If splash potential or dusty operations, wear goggles/faceshield.

Skin protection

Hand protection Chemical resistant gloves.

Other

While monoclonal antibodies are not anticipated to be readily absorbed through the skin, wear impervious gloves and body covering (i.e. lab coat) to minimize skin contact.

Respiratory protection Not required under normal conditions for liquid handling activities. If handling powder forms, consider appropriate respiratory protection to maintain exposure levels below occupational exposure level (OEL).

Thermal hazards Not available.

General hygiene considerations Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

9. Physical and chemical properties

Appearance

Physical state Liquid.

Form	Aqueous solution.
Color	Clear to cloudy.
Odor	Odorless
Odor threshold	Not available.
pH	Neutral
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not applicable.
Upper/lower flammability or explosive limits	
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	Not available.
Vapor density	Not available.
Relative density	Not available.
Solubility(ies)	
Solubility (water)	Soluble.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Explosive properties	Not explosive.
Oxidizing properties	The substance or mixture is not classified as oxidizing.

10. Stability and reactivity

Reactivity	Not water reactive.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	Hazardous polymerization does not occur.
Conditions to avoid	None under normal conditions.
Incompatible materials	Strong oxidizing agents.
Hazardous decomposition products	No hazardous decomposition products are known.

11. Toxicological information

Information on toxicological effects

Acute toxicity	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	
Respiratory sensitization	Due to lack of data the classification is not possible.
Skin sensitization	Due to lack of data the classification is not possible.

Germ cell mutagenicity	Mutagenicity testing has not been conducted. This substance is a monoclonal antibody. It does not possess mutagenic potential. (Galcanezumab) Based on available data, the classification criteria are not met.
Carcinogenicity	Not listed by IARC, NTP, ACGIH or OSHA. Based on available data, the classification criteria are not met.
IARC Monographs. Overall Evaluation of Carcinogenicity	
Not listed.	
OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)	
Not regulated.	
US. National Toxicology Program (NTP) Report on Carcinogens	
Not listed.	
Reproductive toxicity	Animal studies did not report any adverse effects on reproductive tissues, fertility, or embryo/fetal development. (subcutaneous) (Galcanezumab) Based on available data, the classification criteria are not met.
Specific target organ toxicity - single exposure	Based on available data, the classification criteria are not met.
Specific target organ toxicity - repeated exposure	No significant adverse effects reported. (subcutaneous) (Galcanezumab) Based on available data, the classification criteria are not met.
Aspiration hazard	Not applicable.
Further information	This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

12. Ecological information

Ecotoxicity	Not expected to be harmful to aquatic organisms.
Persistence and degradability	Not available.
Bioaccumulative potential	Not available.
Mobility in soil	Not available.
Other adverse effects	Not available.

13. Disposal considerations

Disposal instructions	Dispose in accordance with all applicable regulations.
------------------------------	--

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not available.

15. Regulatory information

US federal regulations This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard Communication Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1052)

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

Issue date 09-19-2018

Revision date 06-07-2019

Version # 05

List of abbreviations LEG: Lilly Exposure Guideline.
TWA: Time Weighted Average Value.

Disclaimer As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

For additional information contact:
Eli Lilly and Company
Hazard Communication
+1-317-651-9533